SciELO - Scientific Electronic Library Online

 
vol.88 número4Infarto agudo de miocardio con elevación del segmento ST en la Argentina. Datos del registro continuo ARGEN-IAM-ST índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

  • Não possue artigos citadosCitado por SciELO

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Revista argentina de cardiología

versão On-line ISSN 1850-3748

Resumo

DUBNER, SERGIO et al. Stroke Prevention In Atrial Fibrillation. Findings From The Gloria-Af Registry. Rev. argent. cardiol. [online]. 2020, vol.88, n.4, pp.290-296. ISSN 1850-3748.  http://dx.doi.org/10.7775/rac.es.v88.i4.18386.

Background:

GLORIA-AF is a prospective, global, 3-phase registry program to determine the safety and effectiveness of dabigatran in patients with newly diagnosed non-valvular atrial fibrillation at risk of stroke. Phase II began when dabigatran, the first non-vitamin K antagonist oral anticoagulant (NOAC), became available.

Objectives:

To describe phase II baseline clinical data in the general population and 2-year follow-up of those patients treated with dabigatran.

Methods:

A total of 15,644 patients were enrolled, 15,308 of whom were eligible and 4,873 received dabigatran. Atrial fibrillation disease characteristics, follow-up findings and concomitant diseases were collected. Data were analyzed using descriptive statistics.

Results:

Of the total eligible patients, 45.5% were female; median age was 71.0 (interquartile range: 64, 78) years. Patients were from Europe (47.9%), North America (22.2%), Asia (20.1%), Latin America (6.0%), and the Middle East/Africa (3.9%). Most had high stroke risk (CHA2DS2-VASc score ≥2; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc =1). Overall, 80.3% received oral anticoagulants, of whom 47.9% received NOACs and 32.4% vitamin K antagonists (VKA); 12.0% received anti-platelet agents; and 7.6% received no antithrombotic treatment. At 2-year follow-up, 70.5% remained on dabigatran.

Conclusions:

Data from GLORIA-AF phase II showed that in non-valvular AF, NOACs have been highly adopted in clinical practice, becoming more frequently prescribed than VKAs. Worldwide, however, a large proportion of patients remain undertreated.

Palavras-chave : Anticoagulants / administration & dosage; Administration, Oral; Atrial Fibrillation Stroke/prevention and control.

        · resumo em Espanhol     · texto em Espanhol     · Inglês ( pdf ) | Espanhol ( pdf )